The following represents disclosure information provided by faculty of the educational and scientific sessions. The Committee have reviewed all presented disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.
 
Jaffer Ajani
 
Employment - No Relationships to Disclose
 
Leadership - No Relationships to Disclose
 
Stock and Other Ownership Interests - No Relationships to Disclose
 
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
 
Consulting or Advisory Role - American Cancer Society; Amgen; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Jazz Pharmaceuticals; Kyowa Kirin International; Merck; Novartis; SERVIER; Vaccinogen; Zymeworks
 
Speakers' Bureau - No Relationships to Disclose
 
Research Funding - Amgen; Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; SERVIER (Inst); Taiho Pharmaceutical; Takeda; Zymeworks
 
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Expert Testimony - No Relationships to Disclose
 
Travel, Accommodations, Expenses - No Relationships to Disclose
 
Other Relationship - No Relationships to Disclose
 
(OPTIONAL) Uncompensated Relationships - No Relationships to Disclose
 
(OPTIONAL) Open Payments Link - No Relationships to Disclose